Clinical Trial Update: Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for MY008211A in patients with paroxysmal nocturnal haemoglobinuria who are naive to complement inhibitor therapy; the study is cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Haemoglobinuria

Drugs mentioned

• MY008211A

Snippet

Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Conditions: Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase 3 | Status: RECRUITING